FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
 HHS Logo links to Department of Health and Human Services website
Skip navigationFDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions
horizonal rule
Dockets Management

Up | AC Home Page

Food and Drug Administration

Advisory Committee for Pharmaceutical Science

October 5-6, 2006

FDA Briefing Information

Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552).  These redacted portions will appear as white space on the screen or on the printed page.

Table of Contents for FDA Backgrounder

  24. The bioequivalence of highly variable drugs and drug products -- K. Midha, Ph.D. (see Bibliography)
  1. Critical Path Opportunities List
  2. Critical Path Initiative Fact Sheet
  3. Topical Drug Classification -- L. Buhse, Ph.D., et. al., (see Bibliography)
  4. Pharmaceutical Nomenclature Issues and Challenges -- M. Nasr, Ph.D., excerpted presentation, ACPS, October 2003
  5. CDER Data Standards Manual Definitions for Topical Dosage Forms
  6. FDA Considerations for Regulation of Nanomaterial Containing Products -- N. Sadrieh, Ph.D., presentation
  7. Nonomaterials Raise New Challenges (see Bibliography)
  8. FDA News: FDA Forms Internal Nanotechnology Task Force
  9. Nanotechnology public meeting -  Federal Register Notice
  10. Applicability of Existing Regulations to the Development of a Dendrimer Nanotechnology-based Pharmaceutical (Summary) -- J. Paull, Ph.D.
  11. Regulatory Approaches To Novel Nonomaterials -- M. Lebovits, Ph.D.
  12. Bibliography

Page last updated September 19, 2006 kkhorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management